Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Citations Over TimeTop 1% of 2012 papers
Abstract
Tryptophan catabolism mediated by indoleamine 2,3-dioxygenase (IDO1) is an important mechanism of peripheral immune tolerance contributing to tumoral immune resistance, and IDO1 inhibition is an active area of drug development. Tryptophan 2,3-dioxygenase (TDO) is an unrelated hepatic enzyme that also degrades tryptophan along the kynurenine pathway. Here, we show that enzymatically active TDO is expressed in a significant proportion of human tumors. In a preclinical model, TDO expression by tumors prevented their rejection by immunized mice. We developed a TDO inhibitor, which, upon systemic treatment, restored the ability of mice to reject TDO-expressing tumors. Our results describe a mechanism of tumoral immune resistance based on TDO expression and establish proof-of-concept for the use of TDO inhibitors in cancer therapy.
Related Papers
- → 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-γ-stimulated monocytes (THP-1 cells)(1993)98 cited
- → Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia(1995)66 cited
- → Effect of indoleamine dioxygenase-1 deficiency and kynurenine pathway inhibition on murine cerebral malaria(2008)24 cited
- → Neuronal localization of indoleamine 2,3-dioxygenase in mice(2005)27 cited
- → IDO-1 mediated tryptophan catabolism – A MIE indicating formaldehyde induced immunotoxicity(2016)